Med Spa Las Vegas

Boey: The World's First Type-E Botulinum Toxin Approved for Aesthetics Arrives with an 8-Hour Onset

Health Canada approved Boey on June 23, 2026, making trenibotulinumtoxinE the first botulinum neurotoxin serotype E cleared for cosmetic use anywhere in the world. The key difference from conventional neuromodulators: results appear in as little as 8 hours and fade within 2 to 3 weeks.

Med Spa Las Vegas · July 6, 2026 · 5 min read

Key takeaways

  • Health Canada approved Boey (trenibotulinumtoxinE) on June 23, 2026, making it the world's first botulinum neurotoxin serotype E approved for aesthetic use
  • Boey's effects on glabellar lines can appear as early as 8 hours after injection, compared to the 3-to-7-day onset typical of conventional neuromodulators
  • Results return to baseline within 2 to 3 weeks, positioning Boey as a short-term preview option for patients curious about injectable neuromodulators before committing to longer-lasting treatments
  • An Allergan Aesthetics survey found 79 percent of consumers wish they could preview aesthetic results before committing, and 80 percent are open to learning about new treatment options
NEW NEUROMODULATOR
Boey by the Numbers: Key Clinical Details
8 hrs
Earliest onset time for Boey's glabellar line improvement after injection, per Allergan Aesthetics clinical data
2-3 wks
Duration of Boey's effects before glabellar lines return to baseline, making it a short-term preview treatment
79%
Share of consumers in an Allergan Aesthetics survey who wish they could preview aesthetic results before committing to longer-lasting treatment
80%
Share of consumers in the same Allergan survey who said they are open to learning about new aesthetic treatment options
June 23, 2026
Date Health Canada approved Boey (trenibotulinumtoxinE) as the world's first botulinum neurotoxin serotype E for aesthetic use

Boey's ultra-fast onset and short duration create a new category in aesthetic neuromodulators: a preview treatment for patients who want to see results before committing to a longer-lasting option.

What Makes Boey Different from Conventional Botulinum Toxins

When most people hear the word Botox, they think of botulinum neurotoxin serotype A, the formulation that has been the foundation of cosmetic neuromodulator treatment for decades. Dysport and Xeomin are also serotype A products, differing in formulation and dosing but sharing the same core molecular classification. A smaller category of botulinum toxin products use serotype B, including Myobloc, which is used primarily for therapeutic rather than cosmetic indications. What has never existed in approved aesthetic medicine, until now, is a serotype E product.

Boey, developed by Allergan Aesthetics, contains trenibotulinumtoxinE, a botulinum neurotoxin serotype E. Health Canada approved Boey on June 23, 2026, for the temporary improvement of moderate-to-severe glabellar lines, the vertical frown lines between the eyebrows commonly called '11' lines, in adults. This makes Boey the first botulinum neurotoxin serotype E approved for aesthetic use anywhere in the world.

The serotype distinction is not merely a biochemical curiosity. Different botulinum toxin serotypes have different mechanisms of action at the nerve-muscle junction and different duration profiles. Serotype A products typically last three to six months and take three to seven days to show results. Serotype E, based on the clinical data supporting Boey's approval, behaves very differently in both onset and duration, which is where the product's main patient-facing value lies.

Onset in Hours, Gone in Weeks: The Preview Proposition

The two numbers that define Boey's clinical profile are 8 hours and 2 to 3 weeks. Results for glabellar line improvement can appear as early as 8 hours after injection, far faster than the several-day onset patients expect from conventional neuromodulators. And those results return to baseline within 2 to 3 weeks, rather than the 3-to-6-month duration typical of serotype A products.

At first glance, a shorter duration might seem like a limitation. Patients who want long-lasting results from their neuromodulator treatment would not find Boey's 2-to-3-week window satisfying as a standalone ongoing treatment. But the product is not primarily positioned for patients with an established neuromodulator routine. It is positioned as a preview tool: a way for patients who are curious about injectable aesthetics but uncertain about committing to a result that will last for months to see what treatment looks like without a long commitment.

Allergan Aesthetics conducted consumer surveys that put context around this positioning. According to the company's data, 79 percent of consumers surveyed said they wish they could preview aesthetic results before committing to a longer-lasting treatment, and 80 percent said they are open to learning about new aesthetic treatment options. Those numbers suggest a meaningful group of potential patients who have been hesitant about conventional neuromodulators specifically because of the multi-month commitment. For that group, Boey offers something genuinely new: the ability to experience what smoother glabellar lines look and feel like, with the understanding that the change will resolve naturally within a few weeks if they decide it is not for them.

What Boey's Approval Means for the Aesthetics Landscape

Health Canada's approval covers Boey for use in Canada, and Allergan Aesthetics has indicated that regulatory review is underway in multiple other countries. The US regulatory process follows its own timeline and standards, so Boey's availability to patients in the United States depends on FDA review, which had not been confirmed as complete as of this writing. Patients in Las Vegas and across the US should watch for FDA developments on Boey's approval status.

Even before direct US availability, the Canadian approval matters for the Las Vegas aesthetics market because it establishes Boey as a real, regulatorily reviewed product with clinical data behind it rather than a theoretical pipeline development. The American Med Spa Association covered the approval as significant industry news, noting its implications for practices that offer neuromodulator treatments. When US regulatory clearance follows, the product will enter a market that is already aware of it and has had time to think about how it fits into patient consultations.

The broader trend in aesthetic medicine is toward more options rather than fewer: more formulations, more duration profiles, more ways to meet patients at different points in their aesthetic journey. Boey's ultra-short duration and rapid onset add a genuinely new position to that option set, one that did not previously exist. For patients who have always been curious about what neuromodulators can do but have hesitated to try them, the product offers a lower-stakes entry point that simply was not available before.

What to Discuss at a Consultation

This article is informational only and is not medical or professional advice. Whether Boey or any other neuromodulator treatment is appropriate for a specific individual depends on their medical history, skin condition, treatment goals, and provider recommendation. Every injectable treatment carries risks and potential side effects that a qualified provider should review before any treatment proceeds.

If you are curious about what neuromodulator treatment looks like, whether that is Boey when it becomes available or a currently approved conventional option, the right first step is a consultation with a licensed aesthetic provider. A consultation is not a commitment to treatment. It is an opportunity to ask questions, understand the full range of options, and make an informed decision. Book a consultation at our Las Vegas med spa and explore what today's aesthetic medicine can offer.

Six Things to Understand About Neuromodulators Before Your First Consultation

Whether you are considering Boey, Botox, or another neuromodulator, understanding the basics helps you ask better questions. Here are six concepts worth knowing.

  1. Serotype Matters: Different botulinum toxin products use different serotypes (A, B, E) that have different mechanisms, onsets, and durations. Boey is serotype E, which is why its onset and duration are so different from conventional serotype A products like Botox or Dysport.
  2. Onset Is Not Immediate for Any Neuromodulator: Even Boey's 8-hour onset is not instant. Conventional serotype A products take 3 to 7 days to show their full effect. Managing expectations about timing is an important part of any neuromodulator consultation.
  3. Duration Varies by Product and Individual: Boey's 2-to-3-week duration is unusually short by design. Conventional neuromodulators last 3 to 6 months on average, but individual results vary based on dose, injection technique, metabolism, and the specific muscles being treated.
  4. Glabellar Lines Are the Starting Point for Boey: Boey is currently approved for glabellar lines (the vertical lines between the eyebrows). Conventional neuromodulators are used for a broader range of indications. Your provider can explain what is within the scope of any given product for your specific concerns.
  5. A Consultation Is Not a Commitment: Walking into a med spa for a neuromodulator consultation does not mean you are committing to treatment. It is an opportunity to ask questions, review options, and make an informed decision about whether any treatment is right for your goals and timeline.
  6. Provider Credentials and Training Matter: All injectable treatments carry risks and potential side effects. The skill, training, and anatomical knowledge of the injector are among the most important factors in a safe and satisfying outcome. Always verify that your provider is licensed and trained for the specific treatment you are considering.

Frequently Asked Questions

What is Boey and what is it approved for?

Boey (trenibotulinumtoxinE) is a botulinum neurotoxin serotype E product developed by Allergan Aesthetics and approved by Health Canada on June 23, 2026, for the temporary improvement of moderate-to-severe glabellar lines in adults. It is the first botulinum neurotoxin serotype E product approved for aesthetic use in the world.

How is Boey different from Botox?

Botox uses botulinum neurotoxin serotype A, which typically takes 3 to 7 days to show results and lasts 3 to 6 months. Boey uses serotype E, which can show results as early as 8 hours after injection and fades within 2 to 3 weeks. The shorter duration positions Boey as a preview option for patients curious about neuromodulators rather than a long-term treatment.

Is Boey available in the United States?

As of the date of this article, Boey has been approved by Health Canada for use in Canada. Regulatory review in the United States and other countries is ongoing. Patients in Las Vegas interested in Boey should consult with their aesthetic provider about its current US FDA approval status.

Who is a good candidate for Boey?

This article is informational only and is not medical advice. Based on Allergan's positioning, Boey may be of particular interest to patients who are curious about neuromodulator treatment but hesitant to commit to multi-month results. A consultation with a qualified, licensed aesthetic provider is the appropriate way to determine whether Boey or any neuromodulator treatment is suitable for any individual.